Inclusion Criteria:

   - Patients must have a diagnosis of neuroblastoma either by histologic verification of
   neuroblastoma and/or demonstration of tumor cells in the bone marrow with increased
   urinary catecholamines.

   - Patients must have high-risk neuroblastoma according to COG risk classification at the
   time of study enrollment.

   - Patients must have at least ONE of the following: 1) Recurrent/progressive disease at
   any time prior to study enrollment, 2) Refractory disease, 3) Persistent disease

   - Patients must have at least ONE of the following: 1) Bone disease, 2) Any amount of
   neuroblastoma tumor cells in the bone marrow, 3) At least one soft tissue lesion that
   meets criteria for a TARGET lesion.

   - Patients must have a Lansky (< 16 years) or Karnofsky (> 16 years) score of at least
   50

   - Patients must have fully recovered from the acute toxic effects of all prior
   chemotherapy, immunotherapy, or radiotherapy prior to entering this study.

   - Patients must not be receiving any other anti-cancer agents or radiotherapy at the
   time of study entry or while on study.

   - Patients must not be receiving other investigational medications (covered under
   another IND) within 30 days of study entry or while on study.

   - Patients must not be receiving chronic systemic corticosteroids at doses greater than
   physiologic dosing (inhaled corticosteroids acceptable).

   - Patient must meet the organ function requirements as stated in the protocol.

Exclusion Criteria:

   - Pregnancy, breast feeding, or unwillingness to use effective contraception during the
   study.

   - Patients status post-allogeneic stem cell transplant are not eligible.

   - Patients who, in the opinion of the investigator, may not be able to comply with the
   safety monitoring requirements of the study.

   - Patients with disease of any major organ system that would compromise their ability to
   withstand therapy.

   - Patients who are on hemodialysis.

   - Patients with an active or uncontrolled infection.

   - Patients with known intraparenchymal brain metastasis at study entry are excluded due
   to poor CNS penetration of SF1126.

   - Known history of human immunodeficiency virus (HIV) infection, hepatitis B, or
   hepatitis C.

   - Patient declines participation in NANT 2004-05, the NANT Biology Study.